₹939.70 Cr
Total Issue Size
₹14,526 (18 shares)
1 Lot Cost (Min. Inv.)
₹9,299.71 Cr
Market Cap (At Upper Band)
₹281.91 Cr (30.0% of Issue)
Anchor Book Allocation
+₹310 (+38.8%)
Grey Market Premium Updated 29 Aug 2026, 04:03 PM IST
Issue Structure & OFS vs Fresh Capital Split
| Offering Parameter / Tranche |
Allocation & Value |
% of Gross Issue |
Strategic Mandate / Terms |
| Fresh Issue (Primary Growth Capital) | ₹200.00 cr (aggregating up to ₹2,000.00 million). | 21.3% | Balance sheet equity expansion directly fueling capex, debt repayment & operations |
| Offer for Sale (OFS - Insiders) | 9,166,000 Equity Shares (aggregating to ₹739.70 cr at ₹807 per share). | 78.7% | Secondary liquidity realization for existing promoters & early institutional funds |
| Gross Total Issue Size | ₹939.70 Cr | 100.0% | Aggregate primary market capital raising at upper price band |
| Net Proceeds Reaching Company | Net Proceeds = ₹200.00 cr minus company's portion of offer expenses. | - | Net growth funds after deducting book building issue & underwriting expenses |
| Anchor Investor Allocation Tranche | ₹281.91 Cr (30.0% of Issue) | Up to 30.0% | Reserved anchor allotment tranche for institutional Qualified Institutional Buyers (QIBs) |
| Pre-IPO WACA Benchmark | WACA per equity share: Promoter Exxora Trading LLP ₹0.20; Promoter Dr. Chandrasekhar Bhaskaran Nair ₹6.90; Investor IBEF III ₹187.14. Issue price ₹807 is 4.31x over PE WACA. | Weighted average cost of acquisition for promoters & early funds |
| Selling Shareholders & Dilution | Selling Shareholders: Promoter Dr. Chandrasekhar Bhaskaran Nair (6.11 mn shares) + Investor IBEF III / Motilal Oswal + other early shareholders. Exxora Trading LLP not selling. |
| Intermediary / Regulatory Entity |
Entity Name / Details |
Statutory Function & Status |
| Book Running Lead Managers (BRLMs) |
SEBI Registered Merchant Bankers / BRLMs |
Issue pricing, underwriting, book building & institutional roadshows |
| Registrar to the Issue |
SEBI Category-I Registrar |
Allotment finalization, Demat share transfer & ASBA refund processing |
| Proposed Listing Exchanges |
NSE / BSE |
Trading segments, ticker assignment & continuous disclosure compliance |
| Regulatory Prospectus Stage |
DRHP / RHP Filed |
SEBI ICDR compliance review & exchange in-principle listing approval |
Revenue Breakdown, Product Mix & Customer Concentration
| Product / Operating Segment |
Share (%) |
Value / Channel |
Truenat Diagnostic Test Kits | 74.0% | ₹1,034.82 Cr |
Diagnostic Devices & Testing Equipment | 26.0% | ₹364.55 Cr |
| Market Segment / Customer Concentration Tier |
Share (%) |
Reported Value |
Concentration & Risk Profile |
| Truenat Diagnostic Test Kits & Cartridges | 74.0% | ₹1,069.81 Cr | High-margin consumable annuity stream |
| Diagnostic Testing Analyzers & Devices | 26.0% | ₹375.88 Cr | Capital equipment placement base |
| Domestic vs Export Revenue Mix | Domestic: 82.2% | Exports: 17.8% | ₹1,188 Cr / ₹257 Cr | Direct sales to 40+ countries |
| Top 1 Customer (Central Medical Services / TB) | 34.2% | ₹494.43 Cr | National public health programs |
| Top 5 Customers (Govt + Diagnostic Chains) | 73.8% | ₹1,067.35 Cr | High institutional concentration |
Capital Allocation (Where the Fresh Money Goes)
| Object of the Offer / Proposed Expenditure |
Amount (₹ Cr) |
% of Fresh Issue |
Deployment Timeline / Purpose |
| Plant, Machinery & Automated Assembly Capex | ₹72.28 Cr | 36.1% | Goa manufacturing expansion |
| Clinical Trials & R&D Platform Capex | ₹50.00 Cr | 25.0% | Next-gen assay development |
| General Corporate Purposes (GCP) | ₹77.72 Cr | 38.9% | Global commercialization |
| Total Fresh Growth Capital | ₹200.00 Cr | 100.0% | Balance Sheet Inflow |
3-Year Audited Financial Health & Margins
| Audited Metric / Line Item |
FY24 |
FY25 |
FY26 |
3-Yr CAGR |
| Revenue from Operations |
₹836.56 Cr |
₹1,020.42 Cr |
₹1,445.69 Cr |
+31.5% |
| EBITDA (Operating Profit) |
₹238.28 Cr (28.5%) |
₹269.74 Cr (26.4%) |
₹330.93 Cr (22.9%) |
+17.9% |
| Profit After Tax (PAT) |
₹101.95 Cr (12.2%) |
₹145.10 Cr (14.2%) |
₹166.59 Cr (11.5%) |
+27.8% |
| Operating Cash Flow (CFO) |
₹9.57 Cr |
₹287.10 Cr |
₹50.39 Cr |
Positive |
| ROCE (Return on Capital) |
17.52% |
18.21% |
16.48% |
Stable |
| Debt-to-Equity (D/E) |
0.21x |
0.13x |
0.35x |
Low Debt |
Governance, Lock-in & Litigation Review
| Shareholder Category / Promoter Group |
Pre-IPO Holding (%) |
Post-IPO Holding (%) |
Mandatory Lock-in Terms & Dilution |
| Promoters (C. Nair & S. Natarajan) | 46.65% | 42.10% | 20% locked for 18 Mos; balance 6 Mos |
| Private Equity (Temasek & Motilal Oswal) | 48.20% | 38.50% | Secondary OFS exit |
| Public & Institutional Allottees | 5.15% | 19.40% | Public float post IPO |
| Litigation Category / Proceedings |
Adjudicating Forum |
Quantifiable Exposure |
Materiality Assessment |
| Direct & Indirect Tax Proceedings | ITAT / Customs | ₹19.18 Cr | Routine direct tax disputes |
| Patent / Intellectual Property Suits | None | ₹0.00 Cr | Global Truenat patents intact |
1. Executive Business Summary & Core Operations
Molbio Diagnostics is bringing lab-grade molecular PCR testing to rural and resource-limited clinics worldwide via its portable Truenat platform. At the issue price of ₹807, the IPO values Molbio at 54.64x FY26 P/E—a reasonable multiple relative to diagnostic peers (64.89x avg)—offering investors a rare high-moat Indian med-tech story.
2. Value Proposition, Products & Operations
Molbio designs, manufactures, and commercializes portable, battery-operated real-time PCR devices (Truenat) and single-use microfluidic test chips. Its platform enables decentralized diagnosis of 30 infectious diseases (TB, COVID, Hepatitis, HIV, HPV) within 1 hour without requiring central lab infrastructure.
3. Industry Dynamics & Market Positioning
The IPO totals ₹939.70 cr at ₹807 per share, comprising a ₹200.00 cr Fresh Issue (21.3%) and a ₹739.70 cr OFS (78.7%). Promoters Dr. Chandrasekhar Bhaskaran Nair (6.11 mn shares) and investor IBEF III / Motilal Oswal (selling part of 14.28 mn shares) are selling, while promoter Exxora Trading LLP retains its 41.2% stake. Fresh proceeds fund R&D infrastructure (₹105.54 cr) and plant machinery (₹72.28 cr).
4. Detailed Financial Trajectory & Margin Analysis
Accounting quality is backed by statutory auditor S.R. Batliboi & Associates LLP (EY network) with zero qualifications. Gross margins are stable at ~60%, and cumulative 3-year CFO/PAT conversion is healthy at 84% (₹347.06 cr CFO vs ₹413.65 cr PAT), though FY26 CFO dipped to ₹50.39 cr due to inventory build-up for export expansion.
5. Promoter Integrity, Governance & Shareholding
Governance is clean: 0% promoter pledge, 50% independent board, and technocrat promoters with 25+ years experience. Related party transactions primarily consist of intra-group R&D royalty to 100% subsidiary Bigtec (capped at 10% of revenue), which eliminates completely on consolidation.
6. Relative Valuation & Benchmark Multiples
| Company Name |
CMP / Issue Price (₹) |
P/E Ratio (x) |
EV / EBITDA (x) |
RoNW / ROCE (%) |
Annual Revenue (₹ Cr) |
| Molbio Diagnostics Limited | ₹807 | 54.6x | 28.2x | 16.5% | ₹1,445.69 Cr |
| Metropolis Healthcare Limited | ₹2,150 | 72.4x | 34.5x | 19.2% | ₹1,350.00 Cr |
| Dr. Lal PathLabs Limited | ₹3,100 | 64.8x | 31.8x | 24.5% | ₹2,220.00 Cr |
| Agappe Diagnostics (Benchmark) | - | 42.0x | 22.0x | 18.0% | ₹650.00 Cr |
| Industry Diagnostic Composite | - | 59.7x | 29.4x | 20.6% | - |
At ₹807, post-issue Mcap is ₹9,299.71 cr, implying an FY26 P/E of 54.64x, P/B of 7.95x, and EV/EBITDA of 28.24x. This represents a discount to listed diagnostic/med-tech peers like Poly Medicure (52.61x), Dr. Lal Pathlabs (62.20x), Metropolis (63.72x), and Vijaya Diagnostics (81.02x), despite Molbio delivering faster top-line growth (31.45% CAGR).
Institutional Research & Regulatory Notice:
This document is a factual, data-driven synthesis of the Draft Red Herring Prospectus (DRHP) / Red Herring Prospectus (RHP) filed with SEBI and relevant stock exchanges. It does not constitute investment advice, financial promotion, or a recommendation to subscribe. Primary market investments carry market risk. Consult a SEBI-registered investment advisor before making allocation decisions.
